Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 | P28074 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.45 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
| ▸ | MMP8 | P22894 | 1/20 | 0.43 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.43 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.43 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.43 |
| ▸ | MME | P08473 | 2/20 | 0.43 |
| ▸ | ACE | P12821 | 2/20 | 0.43 |
| ▸ | NOS3 | P29474 | 1/20 | 0.43 |
| ▸ | NOS1 | P29475 | 1/20 | 0.43 |
| ▸ | NOS2 | P35228 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MPO | P05164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2297582 | 0.99 | PSMB5 (0.47) | PSMB5MAPTALDH1A1RECQLCTNNB1 | |
| Alanine SCHEMBL671385 | 0.98 | PSMB5 (0.46) | PSMB5MAPTALDH1A1RECQLCTNNB1 | |
| Levacetylleucine SCHEMBL6674776 | 0.91 | PSMB5 (0.48) | PSMB5ALDH1A1MMP2MMP9MMP8 | |
| Leucine SCHEMBL27471555 | 0.90 | MAPT (0.47) | PSMB5MAPTALDH1A1RECQLCTNNB1 | |
| Leucine SCHEMBL6672109 | 0.89 | MAPT (0.50) | MAPTALDH1A1RECQLCTNNB1SLC1A3 | |
| Leucine SCHEMBL27470583 | 0.89 | MAPT (0.50) | MAPTALDH1A1RECQLCTNNB1SLC1A3 | |
| SCHEMBL660499 | 0.84 | CTNNB1 (0.59) | MAPTALDH1A1RECQLCTNNB1SLC1A3 | |
| SCHEMBL93516 | 0.84 | CTNNB1 (0.59) | MAPTALDH1A1RECQLCTNNB1SLC1A3 | |
| SCHEMBL29482763 | 0.84 | CTNNB1 (0.59) | MAPTALDH1A1RECQLCTNNB1SLC1A3 | |
| SCHEMBL29397866 | 0.84 | CTNNB1 (0.59) | MAPTALDH1A1RECQLCTNNB1SLC1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1123412-B1 | METHOD FOR MONITORING PROTEASOME INHIBITOR DRUG ACTION | MILLENNIUM PHARM INC (US) | 2004-10-06 | — | — | EP | claimed |
| WO-2002101012-A9 | REGULATION OF TRANSGENE EXPRESSION FOLLOWING AAV TRANSDUCTION | CHILDREN S HOSPITAL RES FOUNDA (US) | 2003-12-18 | — | — | WO | claimed |
| US-6613541-B1 | Pharmacology; bioassay; proteolysis; enzyme inhibitors; use to provide guidance for selecting dose amount and dose frequency of proteasome inhibitors for treatment of cancer, inflammatory and autoimmune diseases | MILLENNIUM PHARMACEUTICALS, INC. | 2003-09-02 | — | — | US | claimed |
| WO-2002101012-A2 | REGULATION OF TRANSGENE EXPRESSION FOLLOWING AAV TRANSDUCTION | CHILDREN'S HOSPITAL RESEARCH FOUNDATION (US) | 2002-12-19 | — | — | WO | claimed |
| EP-1123412-A1 | METHOD FOR MONITORING PROTEASOME INHIBITOR DRUG ACTION | Millennium Pharmaceuticals, Inc. (US) | 2001-08-16 | — | — | EP | claimed |
| WO-2000023614-A1 | METHOD FOR MONITORING PROTEASOME INHIBITOR DRUG ACTION | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2000-04-27 | — | — | WO | claimed |
| US-20130310320-A1 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-11-21 | — | — | US | disclosed |
| US-8378099-B2 | Boronic ester and acid compounds, synthesis and uses | MILLENNIUM PHARMACUETICALS, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-20110306560-A1 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-12-15 | — | — | US | disclosed |
| US-8003791-B2 | Boronic ester and acid compounds, synthesis and uses | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-20090247731-A1 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| EP-0788360-B3 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | MILLENNIUM PHARM INC (US) | 2009-08-12 | — | — | EP | disclosed |
| US-7531526-B2 | Boronic ester and acid compounds, synthesis and uses | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-05-12 | — | — | US | disclosed |
| WO-2000023614-A1 | METHOD FOR MONITORING PROTEASOME INHIBITOR DRUG ACTION | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2000-04-27 | — | — | WO | disclosed |
| WO-1999015183-A9 | PROTEASOME INHIBITORS, UBIQUITIN PATHWAY INHIBITORS OR AGENTS THAT INTERFERE WITH THE ACTIVATION OF NF-λB VIA THE UBIQUITIN PROTEASOME PATHWAY TO TREAT INFLAMMATORY AND AUTOIMMUNE DISEASES | PROSCRIPT INC (US) | 1999-07-29 | — | — | WO | disclosed |
| WO-1999015183-A1 | PROTEASOME INHIBITORS, UBIQUITIN PATHWAY INHIBITORS OR AGENTS THAT INTERFERE WITH THE ACTIVATION OF NF-λB VIA THE UBIQUITIN PROTEASOME PATHWAY TO TREAT INFLAMMATORY AND AUTOIMMUNE DISEASES | PROSCRIPT INC. (US) | 1999-04-01 | — | — | WO | disclosed |
| US-5780454-A | Boronic ester and acid compounds | PROSCRIPT, INC. (US) | 1998-07-14 | — | — | US | disclosed |
| EP-0788360-A4 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | PROSCRIPT INC (US) | 1998-05-06 | — | — | EP | disclosed |
| EP-0788360-A1 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | PROSCRIPT, INC. (US) | 1997-08-13 | — | — | EP | disclosed |
| WO-1996013266-A1 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | PROSCRIPT, INC. (US) | 1996-05-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306560-A1 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | BCL6, BCAP31, CD79B | PSMB5 2158/4885MAPT 4135/4885ALDH1A1 3283/4885 |
| US-20090247731-A1 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | BCL6, BCAP31, CD79B | PSMB5 2158/4885MAPT 4135/4885ALDH1A1 3283/4885 |
| US-20130310320-A1 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | BCL6, BCAP31, CD79B | PSMB5 2158/4885MAPT 4135/4885ALDH1A1 3283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.